Vol. I · No. 1 · Taipei EditionThursday, 14 May 2026 · 2026-W20Last ingest 3d ago · 4/4 feeds

Agency Intel / TW

“Truth · Timing · Tradecraft” — the WPP Media Taiwan review-readiness desk
Dashboard · Roster · MNC Pharma · AstraZeneca Taiwan
№ 99 · The AstraZeneca Taiwan dossier

AstraZeneca Taiwan

台灣阿斯特捷利康股份有限公司
Parent: AstraZeneca PLC (LSE: AZN; NASDAQ: AZN)
Readiness
95
Held
Capped at 95. High confidence — AOR sourced within 3y.
Workspace · saved locally in your browser
Pipeline status
Your notes · AstraZeneca Taiwan
Saves on blur. Stored in your browser only — not synced.

AstraZeneca Taiwan is a top-5 MNC pharma in Taiwan, founded 1999 via Astra-Zeneca merger; AstraZeneca Taiwan (台灣阿斯特捷利康) headquartered in Taipei. Globally AstraZeneca surpassed US$50B revenue 2024 and is on track for US$80B by 2030 — fastest-growing big pharma. Taiwan portfolio is HEAVILY oncology-weighted: Tagrisso is dominant EGFR-mutated NSCLC therapy in TW (lung cancer = #1 cancer killer in Taiwan, EGFR mutation prevalence ~50%+ in TW NSCLC — geographically the most important market outside China/Japan for Tagrisso). Imfinzi, Enhertu, Lynparza all major. Forxiga is major CVRM driver. Taiwan Rx DTC restricted (藥事法); consumer-facing spend is (a) corporate brand (CSR/health innovation), (b) unbranded disease-awareness (lung cancer screening, heart failure, severe asthma, lupus), (c) patient association work (Taiwan Lung Cancer Society, TW Diabetes Assoc, TW Rheumatology), (d) HCP digital + medical congresses. COVID-19 vaccine era (Vaxzevria) created brief consumer-facing footprint 2021-2022; now wound down. Estimated NT$250-450M ad spend, mid-tier.

Signal timeline · last 90 days
0 of 0 shown
No signals captured in the last 90 days. Account is monitored daily — next ingest will pick up MOPS filings + RSS hits automatically.
The arithmetic of 95
score breakdown
AOR 8y with Mindshare (WPP — global media AOR since 2018); creative mixed (VML/WPP, McCann Health/IPG, Saatchi Wellness/Publicis split by therapy)aor_anniversary_5y+50
Intel depth (6 wedges · M&A, recent)research_depth+47
Total · capped 9595
30-day signal trajectory
0 signals · spend N/A
Intel wedges
6/8
6 of 8 wedges corroborated. Research confidence: medium.
Open playbook →
Recommended posture
Pitch now.
Global media AOR: Mindshare (WPP) has held the AstraZeneca global media account since 2018 — one of WPP's flagship pharma wins, RENEWED multiple times since (most recently confirmed through 2024). This is a CORE WPP INCUMBENT relationship.